## Clinical Assessment This patient presents with **haemodynamically stable** atrial fibrillation with rapid ventricular response (RVR). The key clinical indicators are: - Systolic BP 158 mmHg (adequate perfusion) - SpO₂ 94% (acceptable oxygenation) - No signs of acute heart failure or cardiogenic shock - Normal troponin (no acute MI) ## Management Strategy for Stable AF-RVR **Key Point:** In haemodynamically stable AF with RVR, the immediate goal is **rate control**, not rhythm control. Rate control is achieved with AV nodal blocking agents. **High-Yield:** The choice of rate control agent depends on: 1. Haemodynamic stability (this patient is stable) 2. Presence of heart failure (absent here) 3. Renal function and drug interactions ## Why Intravenous Diltiazem? | Agent | Onset | Route | Haemodynamic Effect | Use in AF-RVR | |-------|-------|-------|---------------------|---------------| | **IV Diltiazem** | 2–5 min | IV bolus | Mild ↓BP, ↓HR | **First-line in stable AF-RVR** | | IV Amiodarone | 10–30 min | IV infusion | Variable BP effect | Reserved for unstable or refractory cases | | Oral Digoxin | 30–60 min | PO | Minimal BP effect | Slower onset; used for chronic rate control | | DC Cardioversion | Immediate | Electrical | Restores sinus rhythm | Reserved for **haemodynamic instability** | **Clinical Pearl:** Diltiazem (a non-dihydropyridine calcium channel blocker) is preferred over beta-blockers in acute AF-RVR because it has a faster onset and is effective in diabetic patients without worsening glucose control. ## Mnemonic: STABLE AF-RVR Management **S** – Symptom assessment (dyspnea, chest pain, syncope?) **T** – Troponin and ECG (rule out ACS) **A** – Anticoagulation (assess stroke risk) **B** – Beta-blocker or **Calcium antagonist** (rate control) **L** – Lab work (TSH, electrolytes, renal function) **E** – Echocardiography (assess structural disease) ## Why NOT the Other Options? 1. **Amiodarone 300 mg bolus:** Amiodarone is a Class III antiarrhythmic with multiple mechanisms. While effective, it is reserved for: - Haemodynamically unstable AF - Refractory AF-RVR despite AV nodal blockade - AF with accessory pathway (WPW) - This patient is stable and does not yet warrant amiodarone. 2. **Oral digoxin 500 mcg:** Digoxin has a slow onset (30–60 minutes) and is used for **chronic rate control** in AF, not acute RVR. In acute settings, IV agents are preferred. Additionally, digoxin has a narrow therapeutic window and risk of toxicity. 3. **Synchronized DC cardioversion:** Cardioversion is indicated **only if the patient is haemodynamically unstable** (hypotension, shock, acute heart failure, or altered consciousness). This patient has adequate BP and oxygenation, so cardioversion is premature and unnecessary. ## Next Steps After Rate Control ```mermaid flowchart TD A[AF with RVR, Haemodynamically Stable]:::outcome --> B{Rate Controlled?}:::decision B -->|No| C[IV Diltiazem 20 mg bolus]:::action C --> D[Repeat in 15 min if needed] B -->|Yes| E[Assess Stroke Risk - CHA₂DS₂-VASc]:::decision E -->|Score ≥ 1| F[Initiate Anticoagulation]:::action E -->|Score 0| G[Aspirin or observation]:::action F --> H[Decide on Rhythm Control vs Rate Control Strategy]:::decision H -->|Paroxysmal/First episode| I[Consider Flecainide or Sotalol]:::action H -->|Persistent/Permanent| J[Continue Rate Control]:::action ``` **Key Point:** After acute rate control is achieved, the next priorities are: 1. **Anticoagulation** (based on CHA₂DS₂-VASc score) 2. **Rhythm vs. rate control strategy** (depends on symptom burden and left ventricular function) 3. **Underlying cause identification** (thyroid disease, structural heart disease, etc.)
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.